

Treating Incontinence for Underlying Mental and Physical Health

NCT05362292

Status	RECRUITING
Phase	Phase 4
Sponsor	University of California, San Francisco
Enrollment	270 participants

Key Eligibility Criteria

Inclusion (7)

- Aged 60 years or older at the time of enrollment
 - Female sex at birth, without surgical or hormonal gender re-assignment therapy
 - Able to walk to the bathroom and use the toilet without assistance
 - Report urinary incontinence starting at least 3 months prior to screening
 - Report that at least half of incontinence episodes occur with a sudden or strong sensation of urgency
- ... and 2 more (see full listing online)

Exclusion (16)

- Prior clinician diagnosis of dementia, or a Montreal Cognitive Assessment (MOCA) score of 17 or lower on screening cognitive evaluation
 - Current use of anticholinergic, beta-3-adrenergic agonist, or other medication designed to improve urgency incontinence symptoms, or use in the past 1 month
 - Initiation, discontinuation, or dose change of dementia medications (such as donepezil, galantamine, memantine, rivastigmine) in the past 1 month (but candidates on stable doses are eligible)
 - Initiation, discontinuation, or dose change of other drugs with strong anticholinergic effects (based on the Beers List) in the past 1 month (but candidates on stable doses are eligible)
 - Initiation, discontinuation, or dose change of other drugs that can affect urinary frequency, including diuretics, in the past 1 month (but candidates on stable doses are eligible)
- ... and 11 more (see full listing online)

Locations (2 total)

Stanford University, Palo Alto, California, United States
University of California San Francisco, San Francisco, California, United States